1
Evidence that it may be a clinical strategy to use MEK inhibitors to treat metastatic uveal melanomas. However, the same issues of a lack of correlation between the in vitro and clinical results when blocking oncogenic MAPK signaling using MEK inhibitors may apply to uveal melanomas. The differential uptake of 3H-radiolabeled compounds that are trapped intracellularly upon metabolic processing all